Trial Profile
A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Riferminogene pecaplasmide (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Registrational; Therapeutic Use
- Acronyms TAMARIS
- Sponsors Sanofi
- 04 Jun 2014 New trial record